Material Agreements

Pursuit Attractions & Hospitality, Inc. amended Fourth Amendment with Bank of America, N.A., as administrative agent (effective 2024-04-26).

“On April 26, 2024, Viad Corp (the “Company”) entered into the Fourth Amendment (the “Amendment”), among the Company, Brewster Inc., as a co-borrower, the other loan parties party thereto, the lenders party thereto and Bank of America, N.A., as administrative agent, which amends the Credit Agreement, dated as of July 30, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among the Company, Bank of America, N.A., as administrative agent, the swing line lender and the lenders and letter of credit issuers party thereto from time to time.”

FULTON FINANCIAL CORP entered into Purchase and Assumption Agreement – Whole Bank, All Deposits with Federal Deposit Insurance Corporation (FDIC), as receiver for Republic Bank (effective 2024-04-26).

“On April 26, 2024, Fulton Bank, National Association (“ Fulton ”), a wholly owned subsidiary of Fulton Financial Corporation (the “ Company ”), acquired substantially all of the assets and assumed substantially all of the deposits and certain liabilities of Republic First Bank, doing business as Republic Bank (“ Republic Bank ”), from the Federal Deposit Insurance Corporation (the “ FDIC ”), as receiver for Republic Bank (the “ Acquisition ”), pursuant to the terms of the Purchase and Assumption Agreement – Whole Bank, All Deposits, effective as of April 26, 2024, among the FDIC, as receiver of Republic Bank, the FDIC and Fulton Bank (the “ Agreement ”).”

QuidelOrtho Corp amended Amendment No. 2 with Bank of America, N.A., as administrative agent (effective 2024-04-25).

“On April 25, 2024, QuidelOrtho Corporation (the “Company”) entered into Amendment No. 2 (the “Amendment”), by and among the Company, the lenders party thereto, and Bank of America, N.A., as administrative agent, which amends that certain Credit Agreement, dated as of May 27, 2022, as amended by Increase Joinder No. 1, dated as of August 4, 2022, and as further amended by Amendment No. 1, dated as of September 8, 2023”

Douglas Elliman Inc. entered into Settlement Agreement with the settlement class valued at $7.75 million within 30 business days of preliminary approval, as well as two $5 million contingent (effective 2024-04-26).

“On April 26, 2024, Douglas Elliman Inc. (the “Company”) and its subsidiary, Douglas Elliman Realty, LLC (collectively, “Douglas Elliman”), entered into a settlement agreement (the “Settlement Agreement”) to resolve on a nationwide basis the pending class action litigations, Gibson v. NAR, No. 4:23-cv-00788-SRB (W.D. Mo.) and Umpa v. NAR, 4:23-cv-00945-SRB (W.D. Mo.) (the “Lawsuits”).”

Blend Labs, Inc. entered into Investment Agreement with Haveli Brooks Aggregrator, L.P. valued at $150 million (effective 2024-04-29).

“On April 29, 2024 (the “Closing Date”), Blend Labs, Inc., a Delaware corporation (the “Company” or “Blend”), entered into an Investment Agreement (the “Investment Agreement”) with Haveli Brooks Aggregrator, L.P. (the “Investor” or “Haveli”) and issued 150,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.00001 per share (the “Series A Preferred Stock”), for an aggregate purchase price of $150 million, or $1,000 per share (the “Issuance”).”

GOLUB CAPITAL DIRECT LENDING CORP amended PNC Facility Amendment with PNC Bank, National Association, as administrative agent for the secured parties, the collateral agent, and a lender, PNC Capital Markets LLC, as structuring agent, and the lenders from time to time party thereto (as amended, the "PNC Facility") (effective 2024-04-23).

“On April 23, 2024, Golub Capital Direct Lending Corporation (“Company”), GDLC Funding LLC (“GDLC Funding”), a direct, wholly owned subsidiary of the Company, GDLC Feeder Fund, L.P. (“GDLC Feeder”) and Golub Onshore GP 3, LLC, a general partner of GDLC Feeder, entered into an amendment (together with certain other documents executed concurrently, the “PNC Facility Amendment”) with respect to the documents governing the revolving credit facility, initially entered into as of March 21, 2022, by and among the Company, GDLC Funding, PNC Bank, National Association, as administrative agent for the secured parties, the collateral agent, and a lender, PNC Capital Markets LLC, as structuring agent, and the lenders from time to time party thereto (as amended, the “PNC Facility”).”

GXO Logistics, Inc. entered into Underwriting Agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC, acting for themselves and as representatives of the several underwriters named therein valued at $1.1 billion (effective 2024-04-25).

“On April 25, 2024, GXO Logistics, Inc. (“GXO”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Goldman Sachs & Co. LLC, acting for themselves and as representatives of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which GXO agreed to issue and sell to the Underwriters $1.1 billion aggregate principal amount of its senior notes, consisting of $600 million in aggregate principal amount of its 6.250% senior notes due 2029 (the “2029 Notes”) and $500 million in aggregate principal amount of its 6.500% senior notes due 2034 (the “2034 Notes,” and together with the 2029 Notes, the “Notes”) in a registered public offering.”

Pyrophyte Acquisition Corp. amended Working Capital Convertible Promissory Note with Pyrophyte Acquisition LLC (effective 2024-04-26).

“on April 26, 2024, the Company amended and restated its previously issued unsecured amended and restated convertible promissory note (as so amended and restated, the “Working Capital Convertible Promissory Note”) with the Sponsor, to extend the Maturity Date”

Pyrophyte Acquisition Corp. entered into Second Extension Note with Pyrophyte Acquisition LLC valued at up to $1.08 million (effective 2024-04-26).

“on April 26, 2024, the Company issued a promissory note to the Sponsor with a principal amount up to $1.08 million (the “Second Extension Note”).”

NKGen Biotech, Inc. entered into Sandia Letter with Sandia Investment Management LP valued at agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to (effective 2024-04-28).

“On April 28, 2024, the Company entered into letter agreements with each of Meteora (the " Meteora Letter ") and Sandia (the " Sandia Letter " and together with the Meteora Letter, the " Letters ") in connection with the Notes.”

NKGen Biotech, Inc. entered into Meteora Letter with Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Capital, LLC valued at agreed not to exercise Repayment Right until Excess Proceeds exceed $10 million in total; Company to (effective 2024-04-28).

“On April 28, 2024, the Company entered into letter agreements with each of Meteora (the " Meteora Letter ") and Sandia (the " Sandia Letter " and together with the Meteora Letter, the " Letters ") in connection with the Notes.”

NKGen Biotech, Inc. amended AR Subscribed Warrants with certain investors valued at exercise price reset to $2.00 per share (effective 2024-04-25).

“On April 25, 2024, the Company amended and restated the Subscribed Warrants, (the " AR Subscribed Warrants "). Among other things, the AR Subscribed Warrants: (i) delay the Investor’s right to convert the Subscribed Warrants on a cashless basis and (ii) reset and cap the exercise price to $2.00 per share for all Subscribed Warrants.”

biote Corp. entered into Settlement Agreement with Dr. Gary S. Donovitz valued at approximately $76.9 million (effective 2024-04-23).

“On April 23, 2024, biote Corp., a Delaware corporation (the “Company”) entered into a Settlement Agreement (the “Settlement Agreement”) with respect to its previously disclosed litigation with one of the Company’s stockholders, Dr. Gary S. Donovitz (“Donovitz”) (the “Donovitz Litigation”).”

GeneDx Holdings Corp. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $75.0 million (effective 2024-04-29).

“On April 29, 2024, GeneDx Holdings Corp. (the “Company”), entered into a sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC, as sales agent and/or principal (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time to or through TD Cowen, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).”

Planet 13 Holdings Inc. amended First Amendment to the Purchase Agreement with VidaCann, LLC; Loop’s Dispensaries, LLC; Ray of Hope 4 Florida, LLC; Loops Nursery & Greenhouses, Inc.; David Loop; Mark Ascik (effective 2024-04-26).

“On April 26, 2024, the parties entered into a First Amendment to the Purchase Agreement (the “First Amendment”) to extend the End Date to May 31, 2024.”

ZeroStack Corp. entered into At-The-Market Issuances Sales Agreement with Aegis Capital Corp. (effective 2024-04-26).

“On April 26, 2024, Flora Growth Corp. (the "Company") entered into an At-The-Market Issuances Sales Agreement (the "Sales Agreement") with Aegis Capital Corp. (the "Agent") pursuant to which the Company may sell from time to time, at its option, common shares through the Agent in its capacity as sales agent.”

FS Credit Real Estate Income Trust, Inc. entered into Amended and Restated Credit Agreement with Barclays Bank PLC valued at Increases lenders' aggregate commitments from $310 million to $425 million; extends revolving credit (effective 2024-04-24).

“On April 24, 2024, the Company, as borrower, entered into an Amended and Restated Credit Agreement with Barclays Bank PLC, as administrative agent and as a lender, certain other lenders, and the other parties thereto.”

FS Credit Real Estate Income Trust, Inc. amended Second Amendment to the Amended and Restated Loan and Servicing Agreement with Wells Fargo Bank, National Association, Massachusetts Mutual Life Insurance Company, C.M. Life Insurance Company valued at Increases spread from 2.025%+0.11% to 2.30%; extends availability period to Sep 20, 2026; extends ma (effective 2024-04-23).

“On April 23, 2024, FS CREIT Finance MM-1 LLC (an indirectly wholly owned subsidiary of FS Credit Real Estate Income Trust, Inc. (the “ Company ”)), as borrower, entered into a Second Amendment to the Amended and Restated Loan and Servicing Agreement, originally dated as of April 27, 2022, with Wells Fargo Bank, National Association, as administrative agent, Massachusetts Mutual Life Insurance Company and C.M. Life Insurance Company, as lenders, and the other parties thereto.”

Deciphera Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Ono Pharmaceutical Co., Ltd. and Topaz Merger Sub, Inc. valued at $25.60 per share (effective 2024-04-29).

“ion (the “ Company ” or “ Deciphera ”), Ono Pharmaceutical Co., Ltd., a Japanese company ( kabushiki kaishi ) (“ Parent ” or “ Ono ”), and Topaz Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Merger Sub will commence a cash tender offer (the “ Offer ”) to acquire all of the issued and outstanding shares of the common stock, par value $0.01 per share, of the Company (“ Company Common Stock ”), at a price per share of $25.60, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable law.”

ADDENTAX GROUP CORP. entered into Private Placement Agreements with certain individual investors valued at $646,800 (effective 2024-04-29).

“On April 29, 2024, Addentax Group Corp., a Nevada corporation (the “Company”) entered into two Private Placement Agreements (the “Agreement”) with certain individual investors (the “Investors”) who are independent third parties, pursuant to which the Company issued to each of the investor 330,000 shares of its common stock, par value $0.001 per share, at a price of $0.98 per share (the “Common Stock”), resulting in aggregate gross proceeds to the Company of $646,800, which closed on the same day.”

Flutter Entertainment plc entered into Indenture with Citibank, N.A., London Branch, as trustee and Wilmington Trust (London) Limited as security agent valued at $525 million and €500 million (effective 2024-04-29).

“On April 29, 2024, Flutter Treasury DAC (the “Issuer”), an indirect, wholly owned subsidiary of Flutter Entertainment plc (the “Company”), issued and sold $525 million aggregate principal amount of USD-denominated 6.375% senior secured notes due 2029 (the “USD Notes”) and €500 million aggregate principal amount of EUR-denominated 5.000% senior secured notes due 2029 (the “EUR Notes” and, together with the USD Notes, the “Notes”), which mature on April 29, 2029, pursuant to an indenture dated as of April 29, 2024, by and among the Issuer, the guarantors named on the signature pages thereto (the “Guarantors”), Citibank, N.A., London Branch, as trustee and Wilmington Trust (London) Limited as security agent (the “Indenture”).”

Cidara Therapeutics, Inc. terminated Mundipharma Collaboration Agreement with Mundipharma Medical Company valued at Termination of Company's rights and obligations under the agreement due to assignment and novation t (effective 2024-04-24).

“Item 1.02 Termination of a Material Definitive Agreement. See Item 1.01 above, which is incorporated by reference into this Item 1.02.”

Cidara Therapeutics, Inc. amended Melinta License Amendment with Melinta Therapeutics, LLC valued at Amendment to Melinta License Agreement modifying regulatory milestones for additional indication. (effective 2024-04-23).

“the Company entered into an amendment, dated April 23, 2024, to the Melinta License Agreement (the “Melinta License Amendment”) that, among other changes, modified the regulatory milestones payable upon receipt of marketing approval of the current rezafungin acetate product for an Additional Indication (as defined in the Melinta License Agreement).”

Cidara Therapeutics, Inc. entered into Novation Agreement with NAPP Pharmaceutical Group Limited valued at Assignment and novation of the Mundipharma Collaboration Agreement and Commercial Supply Agreement f (effective 2024-04-24).

“The Company, NAPP and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Commercial Supply Agreement from the Company to NAPP (the “Novation Agreement”).”

Cidara Therapeutics, Inc. entered into Asset Purchase Agreement with NAPP Pharmaceutical Group Limited valued at Sale of rezafungin acetate assets and associated rights in exchange for assumption of liabilities an (effective 2024-04-24).

“On April 24, 2024, the Company and NAPP Pharmaceutical Group Limited, a company organized under the laws of England (“NAPP”), and an affiliate of Mundipharma Medical Company (“Mundipharma”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company sold to NAPP, effective as of April 24, 2024, all of the Company’s rezafungin acetate assets, including all of the Company’s right to receive future milestones and royalties under the License Agreement, dated July 26, 2022 between the Company and Melinta Therapeutics, LLC, as amended, (the “Melinta License Agreement”) and the License and Collaboration Agreement dated September 3, 2019 between the Company and Mundipharma, as amended, (the “Mundipharma Collaboration Agreement”), all rezafungin intellectual property rights, including patents and know-how, all product data, regulatory approvals and documentation, rezafungin and comparator inventory, specified prepaid assets and specified contracts, in exch”

SmartStop Self Storage REIT, Inc. amended NPA Amendment (effective 2024-04-26).

“On April 26, 2024, SmartStop Self Storage REIT, Inc. (the “Company”) amended the Note Purchase Agreement dated April 19, 2022 (the “NPA Amendment”).”

AUDDIA INC. entered into securities purchase agreement with accredited investors valued at $2,314,000 (effective 2024-04-23).

“On April 23, 2024, Auddia Inc. (the “Company”, “we” and “us”) entered into a securities purchase agreement with accredited investors for a convertible preferred stock and warrants financing.”

Nu-Med Plus, Inc. entered into Share Exchange Agreement with YourSpace America, Inc. (effective 2024-04-25).

“On April 25, 2024, Nu-Med Plus, Inc. (the " Company ") entered into a Share Exchange Agreement (the " Share Exchange Agreement ") for the merger of YourSpace America, Inc. (" YSA ") into the Company (the " Transaction ").”

Kosmos Energy Ltd. amended A&R RBL valued at $1.35 billion (effective 2024-04-25).

“On April 25, 2024, Kosmos Energy Ltd. (the “ Company ”) amended and restated its existing commercial debt facility by entering into an amended and restated facility agreement (the “ A&R RBL ”) and certain ancillary documents.”

AUGUSTA GOLD CORP. amended Amended Schedule A with Augusta Investments Inc. valued at $1,500,000 (effective 2024-04-26).

“On April 26, 2024, Augusta Gold Corp. a Nevada corporation (the "Company"), executed an amended Schedule A (the "Amended Schedule A") to its amended and restated secured promissory note issued to Augusta Investments Inc.”

CapForce Inc. entered into Agreement with Camtech Pte Ltd valued at $218,000 (effective 2024-04-23).

“On April 23, 2024, OpGen, Inc. (the “Company”) entered into a letter agreement (the “Agreement”) with Camtech Pte Ltd, a Singaporean family office (“Camtech”), for the sale of certain of the Company’s inventory and customer contracts for its Unyvero products.”

COLLEGIUM PHARMACEUTICAL, INC entered into Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. (effective 2024-04-26).

“On April 26, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into an Authorized Generic Agreement (the “AG Agreement”) with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which the Company granted to Hikma certain rights relating to an authorized generic version of the Company’s Nucynta IR product (the “Nucynta IR Authorized Generic”) and the Company’s Nucynta ER product (the “Nucynta ER Authorized Generic” and, collectively, the “Nucynta AG Products”) in the United States.”

DNA X, Inc. entered into Lock-Up Agreement with the Purchaser (effective 2024-04-29).

“In addition, on April 29, 2024, in connection with the entry into the Subscription Agreement, the Company and the Purchaser entered into a lock-up agreement (the “Lock-Up Agreement”).”

DNA X, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2024-04-29).

“On April 29, 2024, in connection with the entry into the Subscription Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.”

DNA X, Inc. entered into Subscription Agreement with an individual investor (the Purchaser) valued at $3,850,000 (effective 2024-04-29).

“On April 29, 2024, Sonim Technologies, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with an individual investor identified in the Subscription Agreement (“Purchaser”), providing for the private placement of (i) 3,500,000 shares of the Company’s common stock, par value $0.001, (“Common Stock”) and (ii) warrants to purchase up to 3,500,000 shares of Common Stock (the “Warrants”) for an aggregate purchase price of $3,850,000 (the “Purchase Price”).”

PHIBRO ANIMAL HEALTH CORP entered into Debt Commitment Letter with Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A. valued at $325 million senior secured incremental first lien term loan facility (effective 2024-04-28).

“Phibro entered into a debt commitment letter (the “Commitment Letter”), dated as of April 28, 2024, with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), Compeer Financial, PCA (“Compeer”) and Citibank, N.A. (“Citibank” and, collectively with Rabobank and Compeer, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325 million (the “Incremental Term Facility”).”

PHIBRO ANIMAL HEALTH CORP entered into Purchase and Sale Agreement with Zoetis Inc. valued at $350 million (effective 2024-04-28).

“On April 28, 2024, Phibro Animal Health Corporation, a Delaware corporation (“Phibro Animal Health”), and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of Phibro Animal Health (together with Phibro Animal Health, “Phibro”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”).”

UMB FINANCIAL CORP entered into Agreement and Plan of Merger with Heartland Financial USA, Inc. and Blue Sky Merger Sub Inc. (effective 2024-04-28).

“On April 28, 2024 (the “Signing Date”), UMB Financial Corporation, a Missouri corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Heartland Financial USA, Inc., a Delaware corporation (“HTLF”) and Blue Sky Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Blue Sky Merger Sub”).”

AZZ INC entered into Underwriting Agreement with Evercore Group L.L.C. and Jefferies LLC as representatives of the several underwriters valued at $67.20 per share (effective 2024-04-25).

“On April 25, 2024, AZZ Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Evercore Group L.L.C. (“Evercore”) and Jefferies LLC (“Jefferies”) as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of 4,000,000 shares of common stock, par value $1.00 per share, of the Company (“Common Stock”), in an underwritten public offering at a purchase price of $67.20 per share (the “Purchase Price”), which reflects a price to the public of $70.00 per share less $2.80 per share (the “Offering”).”

Aptose Biosciences Inc. amended Amended and Restated Warrant to Purchase Common Shares with Hanmi Pharmaceutical Co., Ltd. valued at 2,339,181 warrants at $1.71 per share (effective 2024-04-24).

“On April 24, 2024, Aptose Biosciences Inc. (the “ Company ”) entered into an Amended and Restated Warrant to Purchase Common Shares (the “ Amended Warrant Agreement ”) with Hanmi Pharmaceutical Co., Ltd. (“ Hanmi ”) in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”).”

DELCATH SYSTEMS, INC. amended Fifth Amendment with Synerx Pharma, LLC and Mylan Teoranta (effective 2024-04-22).

“On April 22, 2024, Delcath Systems, Inc. (“Delcath”) entered into a Fifth Amendment, effective May 1, 2024 (the “Amendment”), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the “Agreement”), for Delcath’s supply of melphalan hydrochloride (the “Product”).”

STAR EQUITY HOLDINGS, INC. entered into Loan and Security Agreement with Keybank National Association valued at up to $4,000,000 (effective 2024-04-24).

“On April 24, 2024, KBS Builders, Inc. (the “Borrower”), a wholly-owned subsidiary of the Star Equity Holdings, Inc. (the “Company”), entered into a Loan and Security Agreement (the “Keybank Loan Agreement”) with Keybank National Association (“Keybank”) providing the Borrower with a working capital line of credit of up to $4,000,000”

Blaize Holdings, Inc. amended Merger Agreement Amendment with BurTech, BurTech Merger Sub Inc., Blaize, Burkhan valued at Increased Base Purchase Price from $700 million to $767 million; revised definitions (effective 2024-04-22).

“On April 22, 2024, BurTech, BurTech Merger Sub Inc., Blaize and Burkhan entered into an Amendment to Agreement and Plan of Merger (the " Merger Agreement Amendment ")”

Blaize Holdings, Inc. entered into Sponsor Forfeiture Agreement with BurTech LP LLC valued at Sponsor agreed to forfeit 2,000,000 BurTech Shares (effective 2024-04-22).

“Backstop Subscription Agreement On April 22, 2024, BurTech LP LLC (the “ Sponsor ”) entered into a backstop subscription agreement (the “ Backstop Subscription Agreement ”) with BurTech and Blaize.”

Blaize Holdings, Inc. entered into Backstop Subscription Agreement with BurTech LP LLC valued at Sponsor shall purchase BurTech Shares if Trust Amount less than $30,000,000 (effective 2024-04-22).

“On April 22, 2024, BurTech LP LLC (the " Sponsor ") entered into a backstop subscription agreement (the " Backstop Subscription Agreement ") with BurTech and Blaize”

Blaize Holdings, Inc. entered into Ava Letter Agreement with Ava Investors SA valued at Concurrent issuance of pre-funded warrants (effective 2024-04-22).

“inancing ”) to Ava Investors SA, a société anonyme incorporated under the laws of Switzerland (“ Ava ”, together with its affiliates and their respective transferees,”

Blaize Holdings, Inc. entered into RT Letter Agreement with RT-AI I, LLC valued at Convertible note financing of up to $125.0 million; $70.0 million funded as of April 22, 2024 (effective 2024-04-22).

“on April 22, 2024, of which $70.0 million were funded to Blaize as of such date, BurTech consented to a letter agreement (the " RT Letter Agreement ") between Blaize and RT-AI I, LLC”

PHOENIX MOTOR INC. entered into Waiver with JAK Opportunities II LLC (effective 2024-04-05).

“As of April 5, 2024, Phoenix Motor Inc., a Delaware corporation (the “Company”), entered into a waiver letter (the “Waiver”) by and between the Company and JAK Opportunities II LLC (the “Investor”), pursuant to which the Investor waived its right to require the Company to sell $12 million of principal amount of the Company’s secured senior convertible promissory note to the Investor pursuant to the Securities Purchase Agreement, dated as of November 10, 2023, with the Investor.”

La Rosa Holdings Corp. amended Amendment with Yeimalis Acevedo-Rasmussen valued at $2,413.99 (effective 2024-04-26).

“On April 26, 2024, La Rosa Holdings Corp., a Nevada corporation (the “Company”), and Yeimalis Acevedo-Rasmussen (“Selling Stockholder”) entered into an amendment agreement (the “Amendment”) to correct an inadvertent error in the original stock purchase agreement, dated March 15, 2024 (the “Purchase Agreement”)”

Berenson Acquisition Corp. I entered into Cable Car Guaranty with certain direct and indirect subsidiaries of Custom Health (effective 2024-04-22).

“Certain direct and indirect subsidiaries of Custom Health also provided a guaranty (the “Cable Car Guaranty”), whereby each of them unconditionally guaranteed, as primary obligor and not merely as surety, the prompt and complete payment and performance when due, whether by demand, acceleration or otherwise, of the obligations of Custom Health under the Cable Car Promissory Note in the currency in which and as such obligations are to be paid or performed”